192 related articles for article (PubMed ID: 14972528)
1. Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats.
Zhao X; Chen FP; Sullender WM
Virology; 2004 Jan; 318(2):608-12. PubMed ID: 14972528
[TBL] [Abstract][Full Text] [Related]
2. Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants.
Zhao X; Chen FP; Megaw AG; Sullender WM
J Infect Dis; 2004 Dec; 190(11):1941-6. PubMed ID: 15529258
[TBL] [Abstract][Full Text] [Related]
3. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
Wu H; Pfarr DS; Johnson S; Brewah YA; Woods RM; Patel NK; White WI; Young JF; Kiener PA
J Mol Biol; 2007 May; 368(3):652-65. PubMed ID: 17362988
[TBL] [Abstract][Full Text] [Related]
4. In vivo selection of respiratory syncytial viruses resistant to palivizumab.
Zhao X; Sullender WM
J Virol; 2005 Apr; 79(7):3962-8. PubMed ID: 15767398
[TBL] [Abstract][Full Text] [Related]
5. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.
DeVincenzo JP; Hall CB; Kimberlin DW; Sánchez PJ; Rodriguez WJ; Jantausch BA; Corey L; Kahn JS; Englund JA; Suzich JA; Palmer-Hill FJ; Branco L; Johnson S; Patel NK; Piazza FM
J Infect Dis; 2004 Sep; 190(5):975-8. PubMed ID: 15295704
[TBL] [Abstract][Full Text] [Related]
6. Palivizumab is highly effective in suppressing respiratory syncytial virus in an immunosuppressed animal model.
Ottolini MG; Curtis SR; Mathews A; Ottolini SR; Prince GA
Bone Marrow Transplant; 2002 Jan; 29(2):117-20. PubMed ID: 11850705
[TBL] [Abstract][Full Text] [Related]
7. New strategies for control of respiratory syncytial virus infection.
Nokes JD; Cane PA
Curr Opin Infect Dis; 2008 Dec; 21(6):639-43. PubMed ID: 18978532
[TBL] [Abstract][Full Text] [Related]
8. Palivizumab for respiratory syncytial virus prophylaxis.
Sandritter T
J Pediatr Health Care; 1999; 13(4):191-5; quiz 196-7. PubMed ID: 10690084
[TBL] [Abstract][Full Text] [Related]
9. Palivizumab in the prophylaxis of respiratory syncytial virus infection.
Cardenas S; Auais A; Piedimonte G
Expert Rev Anti Infect Ther; 2005 Oct; 3(5):719-26. PubMed ID: 16207163
[TBL] [Abstract][Full Text] [Related]
10. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.
Giebels K; Marcotte JE; Podoba J; Rousseau C; Denis MH; Fauvel V; Laberge S
Pediatr Pulmonol; 2008 Feb; 43(2):169-74. PubMed ID: 18085710
[TBL] [Abstract][Full Text] [Related]
11. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC
Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
[TBL] [Abstract][Full Text] [Related]
12. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
Simoes EA; Groothuis JR; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick LM; Kimpen JL;
J Pediatr; 2007 Jul; 151(1):34-42, 42.e1. PubMed ID: 17586188
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
Mahadevia PJ; Malinoski FJ
Arch Pediatr Adolesc Med; 2007 May; 161(5):519-20; author reply 520. PubMed ID: 17485634
[No Abstract] [Full Text] [Related]
14. Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol.
Wyde PR; Laquerre S; Chetty SN; Gilbert BE; Nitz TJ; Pevear DC
Antiviral Res; 2005 Oct; 68(1):18-26. PubMed ID: 16112208
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats.
Wyde PR; Moore DK; Hepburn T; Silverman CL; Porter TG; Gross M; Taylor G; Demuth SG; Dillon SB
Pediatr Res; 1995 Oct; 38(4):543-50. PubMed ID: 8559607
[TBL] [Abstract][Full Text] [Related]
16. Age-related differences in pulmonary cytokine response to respiratory syncytial virus infection: modulation by anti-inflammatory and antiviral treatment.
Boukhvalova MS; Yim KC; Kuhn KH; Hemming JP; Prince GA; Porter DD; Blanco JC
J Infect Dis; 2007 Feb; 195(4):511-8. PubMed ID: 17230410
[TBL] [Abstract][Full Text] [Related]
17. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry.
Frogel M; Nerwen C; Cohen A; VanVeldhuisen P; Harrington M; Boron M;
J Perinatol; 2008 Jul; 28(7):511-7. PubMed ID: 18368063
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis.
Oliveira DB; Iwane MK; Prill MM; Weinberg GA; Williams JV; Griffin MR; Szilagyi PG; Edwards KM; Staat MA; Hall CB; Durigon EL; Erdman DD
J Clin Virol; 2015 Apr; 65():26-31. PubMed ID: 25766983
[TBL] [Abstract][Full Text] [Related]
19. Economic analysis of palivizumab in infants with congenital heart disease.
Yount LE; Mahle WT
Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of RSVIG prophylaxis and therapy of respiratory syncytial virus in an immunosuppressed animal model.
Ottolini MG; Porter DD; Hemming VG; Zimmerman MN; Schwab NM; Prince GA
Bone Marrow Transplant; 1999 Jul; 24(1):41-5. PubMed ID: 10435733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
